Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Bioethics; Legal Ethics; Medical Ethics; Research; Health Law; Administrative Law; Technology (1)
- Casinos; Gambling; Gaming; Surveillance (1)
- Checking Accounts; Banking Law; Legislation (1)
- Drugs (1)
- Evidence; Witnesses; Eyewitnesses; Criminal Law; Civil Law & Procedure; Technology; Forensics (1)
-
- Freedom of Speech; First Amendment; Constitutional Law; Sexual Exploitation of Children; (1)
- Freedom of Speech; First Amendment; Constitutional Law;Technology; Drones (1)
- Genetics; Technology; Privacy; Patient Confidentiality (1)
- Health Care; Constitutional Law; Congress; Administrative Law; Prescription Drugs (1)
- Health Care; Prescription Drugs; Administrative Law (1)
- Health Law; Employment Law; Genetics; Model Acts (1)
- Intellectual Property; Patents; Legislation; Prescription Drugs (1)
- Prescription Drugs; Public Health (1)
- Prescription; Health Care; Technology; Medical Ethics (1)
- State Law; Cities & Municipalities; DNA; Evidence; Criminal Records (1)
- Technology; Legal Ethics (1)
Articles 1 - 16 of 16
Full-Text Articles in Law
Hardware, Heartware, Or Nightmare: Smart-City Technology And The Concomitant Erosion Of Privacy, Leila Lawlor
Hardware, Heartware, Or Nightmare: Smart-City Technology And The Concomitant Erosion Of Privacy, Leila Lawlor
Faculty Publications By Year
Smart city technology is being adopted in cities all around the world to simplify our lives, save us time, ease traffic, improve education, reduce energy usage and keep us safe. This article discusses smart city projects being utilized in crime prevention and investigations. Specifically, this article highlights examples of gunshot detection devices and surveillance that have led to improvements in public safety in Cape Town, Chicago and Atlanta, and discusses their impacts to privacy.
Regulating Drug Promotion To Promote The Public Health: A Response To Bennett, Et Al., Patricia J. Zettler
Regulating Drug Promotion To Promote The Public Health: A Response To Bennett, Et Al., Patricia J. Zettler
Faculty Publications By Year
No abstract provided.
Compassionate Use Of Experimental Therapies: Who Should Decide?, Patricia J. Zettler
Compassionate Use Of Experimental Therapies: Who Should Decide?, Patricia J. Zettler
Faculty Publications By Year
In addition to being an example of unsubstantiated hype about regenerative medicine, the controversy around the Italy-based Stamina Foundation's unproven stem cell therapy represents another chapter in a continuing debate about how to balance patients' requests for early access to experimental medicines with requirements for demonstrating safety and effectiveness. Compassionate use of the Stamina therapy arguably should not have been permitted under Italy's laws, but public pressure was intense and judges ultimately granted access. One lesson from these events is that expert regulatory agencies may be the institutions most competent to make compassionate use decisions and that policies should include …
Regulatory Competitive Shelters In The Area Of Personalized Medicine, Yaniv Heled
Regulatory Competitive Shelters In The Area Of Personalized Medicine, Yaniv Heled
Faculty Publications By Year
No abstract provided.
Avoiding Ethical Problems In Social Media, Nicole G. Iannarone
Avoiding Ethical Problems In Social Media, Nicole G. Iannarone
Faculty Publications By Year
No abstract provided.
The First Amendment And The Rpas, Caren M. Morrison
The First Amendment And The Rpas, Caren M. Morrison
Faculty Publications By Year
No abstract provided.
Shadow Dwellers: The Underregulated World Of State And Local Dna Databases, Stephen Mercer, Jessica D. Gabel
Shadow Dwellers: The Underregulated World Of State And Local Dna Databases, Stephen Mercer, Jessica D. Gabel
Faculty Publications By Year
No abstract provided.
Patents Vs. Statutory Exclusivities In Biological Pharmaceuticals - Do We Really Need Both?, Yaniv Heled
Patents Vs. Statutory Exclusivities In Biological Pharmaceuticals - Do We Really Need Both?, Yaniv Heled
Faculty Publications By Year
On March 23, 2010, President Obama signed into law the Biologics Price Competition and Innovation Act (BPCIA) as part of the Patient Protection and Affordable Care Act (also known as the Healthcare Bill). BPCIA sets up a framework for the approval of generic biologics and provides for up to 12.5 years of market exclusivity for FDA approved bio-pharmaceutical products. The exclusivity is intended to run in parallel and in addition to any patents that may apply to such approved bio-pharmaceutical products, which would also grant the developers of these products monopolies in the underlying technologies on which such bio-pharmaceutical products …
Csi Las Vegas: Privacy, Policing, And Profiteering In Casino Structured Intelligence, Jessica D. Gabel
Csi Las Vegas: Privacy, Policing, And Profiteering In Casino Structured Intelligence, Jessica D. Gabel
Faculty Publications By Year
Casinos are powerhouses of information gathering and distribution and use their surveillance activities to police, protect, and profit. The private information does not exist in a vacuum; casinos share it with other casinos and, in some cases, law enforcement. But who protects the consumer in the event that the information is breached or the company is sold or files for bankruptcy? Are there restrictions on the information that casinos may share with law enforcement? This Article argues that the intricate, vast amounts of consumer information compiled through casino structured intelligence ("CSI") require greater protection and oversight in the contexts of …
From A Constitutional Right To A Policy Of Exceptions: Abigail Alliance And The Future Of Access To Experimental Therapy, Patricia J. Zettler, Seema K. Shah
From A Constitutional Right To A Policy Of Exceptions: Abigail Alliance And The Future Of Access To Experimental Therapy, Patricia J. Zettler, Seema K. Shah
Faculty Publications By Year
Although there has been considerable attention to the plight of terminally ill patients with highly sympathetic constitutional and contractual claims that they should be permitted access to unapproved drugs, courts have been appropriately reluctant to grant such claims. Congress and administrative agencies have the requisite institutional competence to decide complex policy issues related to science and health care such as those involved in establishing an expanded access program. Congress and FDA should allow only limited access to unapproved therapies because there are significant concerns about the safety and efficacy of unapproved drugs. Moreover, many of the proposals to widen access …
The Implications Of Post-Phase 1 And "Off-Label" Treatment Use Of Experimental Drugs: How Expansive Should Expanded Access Be?, Patricia J. Zettler
The Implications Of Post-Phase 1 And "Off-Label" Treatment Use Of Experimental Drugs: How Expansive Should Expanded Access Be?, Patricia J. Zettler
Faculty Publications By Year
No abstract provided.
Implementation Of The Check Clearing For The 21st Century Act, Mark E. Budnitz
Implementation Of The Check Clearing For The 21st Century Act, Mark E. Budnitz
Faculty Publications By Year
No abstract provided.
The First Amendment And "Virtual" Child Pornography, Michael B. Landau
The First Amendment And "Virtual" Child Pornography, Michael B. Landau
Faculty Publications By Year
No abstract provided.
Genetic Confidentiality: What's The Big Secret?, Paul A. Lombardo
Genetic Confidentiality: What's The Big Secret?, Paul A. Lombardo
Faculty Publications By Year
No abstract provided.
Controversial Science In The Courtroom: Daubert And The Law's Hubris, Paul S. Milich
Controversial Science In The Courtroom: Daubert And The Law's Hubris, Paul S. Milich
Faculty Publications By Year
No abstract provided.
A Regulatory Model For Genetic Testing In Employment, Jack F. Williams
A Regulatory Model For Genetic Testing In Employment, Jack F. Williams
Faculty Publications By Year
No abstract provided.